CDH17 and adenocarcinoma: With respect to the second aforementioned criterion, we contend that CDH17’s promise as an oncologic target is clear: it is overexpressed by a variety of adenocarcinomas, is associated with metastatic spread and poor prognosis, and has outperformed several other biomarkers as a diagnostic tool.